Learn More
OBJECTIVES To evaluate equivalence in efficacy for rheumatoid arthritis (RA) and compare the safety of the biosimilar HD203 with innovator etanercept (ETN) plus methotrexate (MTX) (ClinicalTrials.gov(More)
(UK) -4.8 (Spain)) vs. 3.2 (1.5 (Germany) -6.6 (Spain), VAS score: 3.8 (range: 3.0 (UK) -4.8 (Italy)) vs. 3.1 (range: 1.9 (Germany) -3.9 (Italy)). ConClusions: Among RA patients receiving adalimumab(More)
  • 1